Markets and sells pharmaceutical products in India across three main buckets: General Medicines (brands like Augmentin and Calpol), Vaccines (Shingrix and others), and a growing Specialty/Oncology portfolio (Trelegy, Nucala, Zejula, Jemperli). FY26 standalone revenue stood at ₹3,821.67 crore with net profit of ₹1,035.98 crore, the first time PAT crossed ₹1,000 crore, and EBITDA margin of 34%, up 290 basis points year-on-year. General Medicines, the largest segment, was held flat by supply disruptions from a contract manufacturer fire (around ₹100 crore impact), while Vaccines delivered double-digit growth of around 11-12% in Q4. The innovation/specialty portfolio has scaled to 6% of Q4 sales from 2% a year ago, with a stated target of 10%, and upcoming launches include Blenrep for multiple myeloma (addressing 40,000+ prevalent patients), Bepirovirsen for hepatitis B, and an RSV vaccine. Inputs costs are dominated by employees at 15.9% of revenue and materials at 11.4%, with capex light at 1.4%, suggesting a marketing and distribution-led model rather than large-scale domestic manufacturing. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. General Medicines, Vaccines, Specialty / Oncology, Innovation portfolio. Brand-driven, asset-light pharmaceutical marketing and distribution with a growing specialty/innovation tilt
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 |
| EBITDA (ex other income) | 773 | 803 | 765 | 1,182 | 1,330 |
| margin % | 23.6 | 24.7 | 22.2 | 31.5 | 34.8 |
| Owners' profit | 1,695 | 611 | 590 | 0 | 1,036 |
| EPS, as reported (₹) | 100.04 | 36.05 | 34.83 | 54.52 | 54.52 |
| ROE % · ROCE % | 63.6 · 26.6 | 35.1 · 41.9 | 33.2 · 40.3 | 47.5 · 57.3 | 45.3 · 55.4 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 811 | 484 | 582 | 1,290 | 903 |
| Capex | (35) | (44) | (31) | (23) | (55) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 |
| Profit before tax | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 |
| Net profit | 253 | 230 | 263 | 205 | 257 | 296 | 278 | 237 |
| EPS (₹) | 14.67 | 13.57 | 15.52 | 12.10 | 15.07 | 16.54 | 16.40 | 14.00 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Corrigendum to postal ballot notice - salary typo fix | compliance | minimal | — | — |
| 1 Sept 2026 · Corrigendum to Postal Ballot Notice - Salary Typo Correction | board shareholder meetings | medium | — | — |
| 26 Aug 2026 · GSK Pharma clarifies volume surge is market driven, no undisclosed info | compliance | low | — | — |
| 26 Aug 2026 · BSE seeks clarification on volume movement | compliance | low | — | — |
| 19 Aug 2026 · Tax refund of Rs 4.99 Cr received for AY 2025-2026 | regulatory legal | medium | — | — |
| 14 Aug 2026 · Postal ballot notice for director appointment and re-appointment | compliance | minimal | — | — |
| 13 Aug 2026 · Postal ballot for director appointments at GSK Pharma | board shareholder meetings | medium | — | — |
| 6 Aug 2026 · GSK Pharma Q1 FY27 transcript: sales up 15%, PAT up 24% | investor communications | low | — | — |
| 6 Aug 2026 · IT Refund of Rs 52 crores received from appeal for AY 1984-85 | regulatory legal | high | — | — |
| 5 Aug 2026 · Analyst meet recording uploaded | investor communications | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| 18.0 |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 45.5 | 28.9 | 125 of 169 | 26% |
| P/B | 20.9 | 3.3 | 160 of 163 | 2% |
| ROCE | 55.3 | 10.8 | 3 of 183 | 99% |
| ROE | 45.3 | 10.4 | 7 of 171 | 97% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 36.1 | 17.5 | 17 of 165 | 90% |
| Revenue growth | 16.6 | 16.3 | 80 of 161 | 51% |
| Profit growth | 15.7 | 30.9 | 94 of 158 | 41% |
| Market cap | 47755 | 839 | 17 of 182 | 91% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
